



ELSEVIER

Seminars in Oncology

AUTHOR INDEX

- Abdalla, E.K., 513
Aleman, A., 33
Alfonsi, M., 822
Alsarrai, M., 363
Anagnostopoulos, A., 33
- Badin, J., 374
Balducci, L., 264
Balkissoon, J., 382
Bardet, E., 822
Barranger, E., 394
Barrett, J., 47
Bassily, N., 374
Batara, J.F., 635
Bauer, J., 363
Becker, K.F., 465
Beer, D.G., 476
Berger, M.S., 659
Bergerot, P., 822
Bethge, W.A., 68
Beutler, T., 374
Bilir, S.P., 827
Birke, M.G., 282
Bishop, M.R., 37, 56
Bonenkamp, J.J., 542
Bourhis, J., 822
Bradley, K.A., 693
Branigan, T., 374
Brenner, B., 554
Brockstein, B., 786
Brown, A., 487
Brown, P.D., 702
Buckner, J.C., 593
- Calais, G., 822
Cassal, R., 363
Champlin, R.E., 22
Chan, A.T.C., 794
Childs, R., 47
Chmura, S.J., 816
Chow, L.W.C., 298
Chung, D., 338
Cody, H.S. III, 311
Cohen, H.J., 149
Cohen, E.E.W., 755
Corry, J., 802
Cox, C.E., 324
Crew, K.D., 450
- Dan, A.G., 374
Darai, E., 394
David, D., 374
DeAngelis, L.M., 684
Denduluri, N., 137
Desprez, B., 822
Duhaime, L., 363
- Ellis, T.L., 653
Enzinger, P.C., 206
Ershler, W.B., 137
- Fanucchi, M., 809
Fowler, D.H., 56
- Gardner, M., 318, 324
Gershenwald, J.E., 415
Gilbert, M.R., 618
Gillani, A.A., 220
Gillison, M.L., 744
Giralt, S., 33
Giuliano, A.E., 426
Giuliano, R., 318, 363
Goguen, L.A., 778
Goyal, A., 304
Grandis, J.R., 734
Gress, R.E., 56
Grossman, S.A., 635
Grunberg, S.M., 220
Gustin, D.M., 769
- Höfler, H., 465
Haddad, R.I., 778
Hainaut, P., 498
Haraf, D.J., 816
Hasina, R., 718
Hormigo, A., 684
Howman-Giles, R., 338
Huang, D.P., 794
- Ilson, D.H., 554
- Jakub, J., 318, 363
Jakub, J.W., 324
James, C.D., 595
Johnson, D.S., 403
- Keles, G.E., 659
Kelsen, D.P., 441
Kemeny, M.M., 175
Khouri, I.F., 22
Khuri, F.R., 809
Kimmick, G., 234
Kitagawa, Y., 409
Kitajima, M., 409
Krammer, P.H., 90
Kwak, L.W., 37
Kwong, A., 298
- Laack, N.N., 702
Lam, C.K., 298
Lambert, R., 498
Lapeyre, M., 822
Law, M., 298
Lesser, G.J., 653
- Lichtman, M.A., 185
Lichtman, S.M., 160
Lin, J., 476
Lingen, M.W., 717, 718
List, M.A., 827
Longo, D.L., 125, 198
Luciani, A., 264
- Macdonald, J.S., 566
MacDonald, T.J., 666
Mahadevan, A., 778
Mansel, R.E., 304
Matsutani, M., 676
Matulonis, U.A., 274
Mayer, R.J., 206
McKnight, T.R., 605
Mehrotra, B., 83
Mehta, M.P., 693
Milano, M.T., 816
Minsky, B.D., 554
Morecki, S., 4
Muss, H.B., 125, 234
- Neelapu, S.S., 37
Neugut, A.I., 450
Ng, P., 374
Norris, C.M., 778
- Or, R., 4
Ott, K., 530
- Packer, R.J., 666
Parkin, D.M., 498
Pendas, S., 318, 324, 363
Pippas, A.W., 324
Pisters, P.W.T., 513
Pomerantz, R.G., 734
Posner, M.R., 778
Posther, K.E., 426
- Quan, M.L., 311
- Raghavan, D., 249
Rai, K.R., 83
Rao, A.V., 149
Rao, R.D., 595
Rasgon, B.M., 382
Reintgen, D., 297, 363
Reintgen, D.S., 318, 324
Resnick, I., 4
Rhein, B., 822
Ries, L.A.G., 128
Rischin, D., 802
Rives, M., 822
Robinson, S., 27
Rood, B.R., 666
Rosseau, D.L. Jr., 415



ELSEVIER

Seminars in Oncology

AUTHOR INDEX

- Abdalla, E.K., 513
Aleman, A., 33
Alfonsi, M., 822
Alsarrai, M., 363
Anagnostopoulos, A., 33
- Badin, J., 374
Balducci, L., 264
Balkissoon, J., 382
Bardet, E., 822
Barranger, E., 394
Barrett, J., 47
Bassily, N., 374
Batara, J.F., 635
Bauer, J., 363
Becker, K.F., 465
Beer, D.G., 476
Berger, M.S., 659
Bergerot, P., 822
Bethge, W.A., 68
Beutler, T., 374
Bilir, S.P., 827
Birke, M.G., 282
Bishop, M.R., 37, 56
Bonenkamp, J.J., 542
Bourhis, J., 822
Bradley, K.A., 693
Branigan, T., 374
Brenner, B., 554
Brockstein, B., 786
Brown, A., 487
Brown, P.D., 702
Buckner, J.C., 593
- Calais, G., 822
Cassal, R., 363
Champlin, R.E., 22
Chan, A.T.C., 794
Childs, R., 47
Chmura, S.J., 816
Chow, L.W.C., 298
Chung, D., 338
Cody, H.S. III, 311
Cohen, H.J., 149
Cohen, E.E.W., 755
Corry, J., 802
Cox, C.E., 324
Crew, K.D., 450
- Dan, A.G., 374
Darai, E., 394
David, D., 374
DeAngelis, L.M., 684
Denduluri, N., 137
Desprez, B., 822
Duhaime, L., 363
- Ellis, T.L., 653
Enzinger, P.C., 206
Ershler, W.B., 137
- Fanucchi, M., 809
Fowler, D.H., 56
- Gardner, M., 318, 324
Gershenwald, J.E., 415
Gilbert, M.R., 618
Gillani, A.A., 220
Gillison, M.L., 744
Giralt, S., 33
Giuliano, A.E., 426
Giuliano, R., 318, 363
Goguen, L.A., 778
Goyal, A., 304
Grandis, J.R., 734
Gress, R.E., 56
Grossman, S.A., 635
Grunberg, S.M., 220
Gustin, D.M., 769
- Höfler, H., 465
Haddad, R.I., 778
Hainaut, P., 498
Haraf, D.J., 816
Hasina, R., 718
Hormigo, A., 684
Howman-Giles, R., 338
Huang, D.P., 794
- Ilson, D.H., 554
- Jakub, J., 318, 363
Jakub, J.W., 324
James, C.D., 595
Johnson, D.S., 403
- Keles, G.E., 659
Kelsen, D.P., 441
Kemeny, M.M., 175
Khouri, I.F., 22
Khuri, F.R., 809
Kimmick, G., 234
Kitagawa, Y., 409
Kitajima, M., 409
Krammer, P.H., 90
Kwak, L.W., 37
Kwong, A., 298
- Laack, N.N., 702
Lam, C.K., 298
Lambert, R., 498
Lapeyre, M., 822
Law, M., 298
Lesser, G.J., 653
- Lichtman, M.A., 185
Lichtman, S.M., 160
Lin, J., 476
Lingen, M.W., 717, 718
List, M.A., 827
Longo, D.L., 125, 198
Luciani, A., 264
- Macdonald, J.S., 566
MacDonald, T.J., 666
Mahadevan, A., 778
Mansel, R.E., 304
Matsutani, M., 676
Matulonis, U.A., 274
Mayer, R.J., 206
McKnight, T.R., 605
Mehrotra, B., 83
Mehta, M.P., 693
Milano, M.T., 816
Minsky, B.D., 554
Morecki, S., 4
Muss, H.B., 125, 234
- Neelapu, S.S., 37
Neugut, A.I., 450
Ng, P., 374
Norris, C.M., 778
- Or, R., 4
Ott, K., 530
- Packer, R.J., 666
Parkin, D.M., 498
Pendas, S., 318, 324, 363
Pippas, A.W., 324
Pisters, P.W.T., 513
Pomerantz, R.G., 734
Posner, M.R., 778
Posther, K.E., 426
- Quan, M.L., 311
- Raghavan, D., 249
Rai, K.R., 83
Rao, A.V., 149
Rao, R.D., 595
Rasgon, B.M., 382
Reintgen, D., 297, 363
Reintgen, D.S., 318, 324
Resnick, I., 4
Rhein, B., 822
Ries, L.A.G., 128
Rischin, D., 802
Rives, M., 822
Robinson, S., 27
Rood, B.R., 666
Rosseau, D.L. Jr., 415

- Rowe, J.M., 185
 Rusch, V.W., 444
- Saha, S., 374
 Sandmaier, B.M., 68
 Sarbia, M., 465
 Schmitz, N., 27
 Schochet, E., 374
 Schulze-Bergkamen, H., 90
 Schwartz, G.K., 574
 Schweitzer, L., 382
 See, S.J., 618
 Seo, P.H., 149
 Shah, M.A., 574
 Shaheen, N.J., 487
 Shapira, M.Y., 4
 Shaw, E.G., 653
 Shivers, S., 363
- Sire, C., 822
 Skinner, E., 249
 Slavin, S., 1, 4
 Spitz, M.R., 726
 Srinivasan, R., 47
 Stanton, C.A., 653
 Starz, H., 357
 Stieber, V.W., 653
 Sturgis, E.M., 726
 Sullivan, C., 778
 Sureda, A., 27
 Swor, G., 318, 363
- Tatter, S.B., 653
 Teo, P.M.L., 794
 Thompson, J.F., 338, 349
 Tishler, R.B., 778
 Tortochaux, J., 822
- Uren, R.F., 338, 349
- van den Bent, M.J., 645
 Vokes, E.E., 717, 786
- Wasil, T., 83
 Weber, W.A., 530
 Wei, Q., 726
 Weiss, L., 4
 Westin, E.H., 198
 Wiese, D., 374
 Wilke, L.G., 333, 426
 Wirth, L., 778
 Wong, J.H., 403
- Yancik, R., 128

SUBJECT INDEX

- Absolute neutrophil count, 10
 ABT-627, 630
 Abuse, of elderly, 291-292
 ABX-EGF, 737, 738-739
 Accutane, 630
 Acetaldehyde, 501
 Acetylaspartate, in brain tumors, 610
 Achalasia, esophageal squamous cell carcinoma and, 488
 ACOSOG Z0010, 430-432
 ACOSOG Z0011, 432-434
 Actinium 225, 70
 Acute myeloid leukemia
 age-dependent cellular abnormalities in, 188-191
 age-specific incidence rates of, 187
 cell biochemical features in, 190
 cell hierarchical features in, 190-191
 cytogenetics in, 188-189, 191
 gene alterations in, 189-190
 newer approaches in, of elderly, 194
 survival rates in, by age, 194
 therapy results of, in elderly, 193-194
 treatment approaches in, 191-193
 treatment variables in, of elderly, 191
 Adenine nucleotide translocator, 98
 Adenocarcinoma
 of gastric cardia, 483-484
 of gastroesophageal junction, 444-445
 genetic changes in, 477
 Lauren's classification of, 467-468
 Adenoma, definition of, 471
 Adenomatous polyposis coli, 480
 Adenomatous polyposis coli gene, 473
 Adjuvant chemotherapy
 in localized gastric cancer, 566-567
 phase III trials of, 639
 principles of, 637
 Administration of Aging, 289
 Adult Protective Service Agencies, 292
 Advance directives, 277-278, 285-286
 AFP, germ cell tumors and, 678-679
 After Mapping of the Axilla: Radiotherapy or Surgery trial, 305-307
 AG1478, 600
 Age
 as cancer risk factor, 264, 266
 sentinel lymph node and, 325
 upper gastrointestinal malignancies and, 457
- Age-standardized rate, definition of, 130-131
 Ageism, 125
 Aging
 cancer and, 265
 cellular v organismal, 138
 chemotherapy and, 160
 competing cancer mortality risks and, 156-157
 familial cancer and, 264
 immunity and, 141-142
 increased cancer incidence with, 142-143
 lymphoma incidence and, 199
 multiple primary malignancies and, 264-266
 normal, 137
 segmental, 198
 theories of, 138-141
 tumor progression and, 143-144
 in US population, 128-129, 132
 Akt, 96-97
 Alanine, in brain tumor, 612
 Alcohol consumption
 esophageal squamous cell carcinoma and, 455, 488
 head and neck cancer and, 728
 upper gastrointestinal malignancies and, 457
 Aldehyde-dehydrogenase enzyme, 501
 ALDH-2, 501
 Alemtuzumab, 85-87
 pretransplant, 34-35
 Allogeneic bone marrow transplantation, graft-versus-malignancy effect following, 47-48
 Allogeneic cell therapy, experimental basis for, 5-6
 Allogeneic cellular immune effector, 53
 Allogeneic transplantation, in Hodgkin's disease, 28-29
 Alloreactive donor lymphocyte, with conventional stem cell transplantation, 6
 ALMANAC trial, 304-306
 AMAROS trial, 305-307
 American College of Surgeons Oncology Group Z0010, 315
 American Joint Commission on Cancer staging system, revised, 420-422
 American Joint Committee on Cancer 2002, for melanoma staging, 416-419
 American Joint Committee on Cancer Sixth Edition staging system, 312
 American Joint Committee on Cancer TNM staging system, for esophageal cancer, 514-516
 American Society of Anesthesiologists' classification, of anesthetic risk, 175-176
 Anal cancer, aging and, 214-215

- Anaplastic astrocytoma, 622
 biologic therapy clinical trials in, 630
 biologic therapy in, 629
 brachytherapy for, 625-626
 clinical presentation of, 618
 diagnostic imaging of, 618-619
 histologic diagnosis of, 619-620
 monitoring of, 621-622
 neoadjuvant chemotherapy for, 628
 obtaining tissue in, 619
 prognostic indicators for, 620-621
 radiation therapy for, 624-625
 recurrent, response rates in, 638
 stereotactic radiosurgery for, 625-626
 surgery for, 622-624
 survival following, 640
- Anastrozole, 240
- Aneuploidy, 720
 esophageal adenocarcinoma and, 480
 in gastroesophageal junction adenocarcinoma, 447
- Angiogenesis, 599, 601, 760-762
- ANT-2, 98-99
- Anti-reflux intervention, 458
- Anti-S100, 357, 358
- Anti-T-lymphocyte globulin, 10
- Antibody therapy, targeted, 68-69
- Antibody-directed cellular cytotoxicity, 68
- Antigen, tumor-associated, 53
- Antigen-presenting cell, 57
- Antimony sulfur colloid, 319
- Antioxidants, upper gastrointestinal malignancies and, 457
- Antisense therapy, 109, 740-741
- AP-1, 102
- Apaf-1, 95, 100, 106
- APC gene/Wnt signaling pathway, 498
- Apoptosis, 90, 103, 479
 drug resistance and, 102-105
 drug-induced, 101-102
 execution of, 93-94
 extrinsic death pathway leading to, 90-93
 induction of, 109
 intrinsic death pathway leading to, 93
 pathways of, defects in, 104-105
 regulation of, 94-96
 RNA interference and, 109
 survival signaling and, interference with, 107-108
 in tumorigenesis, 96-101
- ARF, 97-98
- As Low As Reasonably Achieved, 299
- Aspirin, upper gastrointestinal malignancies and, 459
- ASPP family, 98
- Assisted living, 290-291
- Astatine 70, 211
- Astrocytoma
 anaplastic, *see* Anaplastic astrocytoma
 definition of, 595
 histologic grading system for, 620
 low-grade, 599-600
 overview of, 596
- ATG, 10
- Atrasentan, 630, 641
- Attorney, durable powers of, 285-286
- Augsburg Consensus, 357-358
- Autologous stem cell transplantation, in Hodgkin's disease, 28
- Axillary lymph node, standard evaluation of, 312-313
- Axillary lymph node dissection, 313
 completion, 325-326
- Axillary lymph node metastasis, in breast cancer, 316
- Axillary Lymphatic Mapping Against Nodal Axillary Clearance trial, 304-306
- B-cell non-Hodgkin's lymphoma, monoclonal antibody purging in, 83
- Balance, in elderly, 151
- Balloon catheter system, 626
- Barium esophagram, esophageal squamous cell carcinoma and, 489
- Barrett carcinoma, resection in, survival following, 549
- Barrett's adenocarcinoma, biological differences in, 447
- Barrett's esophagus
 diagnosis of, 492, 515-516
 endoscopic surveillance of, 492-493
 esophageal adenocarcinoma and, 490
 gastroesophageal reflux disease and, 454-455
 short-segment, 516
- Barrett's metaplasia, genetic changes in, 477
- Basaloid squamous cell carcinoma, in esophagus, 467
- Bax, 99-100
- BB-251, 630
- Bcl-2, 95, 99, 106
- Bcl-2 family, 94
- BCL2, 479
- BEACOPP regimen, 27
- Beta-catenin, 479-480, 503
- Bevacizumab, 583
- BH3-mimetics, 106
- Billing, balanced, 286-287
- Biomarker, for head and neck cancer chemoprevention, 771
- Bismuth 70, 213
- Bladder cancer
 bladder preservation in, 252
 metastatic, 254-255
 operative therapy of, in elderly, 251-252
 radiotherapy of, in elderly, 252-254
 survival in, by age, 253
- Bleomycin, 798, 799
 dosing of, in renal dysfunction, 163
- Bleomycin, mechlorethamine, doxorubicin, vinblastine, vincristine, etoposide, prednisone, granulocyte colony-stimulating factor regimen, 27
- Blood, marrow v, in stem cell transplantation, 43
- Blood metastasis, in breast cancer, 316
- Blood-brain barrier, 628-629
- Blue dye technique, 318, 326, 354, 368, 376
- BMI, *see* Body mass index
- BMP-2, in medulloblastoma, 669
- Body mass index
 cancer and, 456
 sentinel lymph node and, 325
 upper gastrointestinal malignancies and, 457
- Bone metastasis, in breast cancer, 316
- Borrmann's classification, 465-466
- Bortezomib, 630, 759-760
- Bowman-Birk inhibitor concentrate, 773-774
- Brachytherapy
 in anaplastic astrocytoma, 625-626
 interstitial, 626
 radiation dose increase via, 559
- Brain metastasis(es)
 chemotherapy in, 698-699
 incidence of, 693
 medical management of, 693-694
 radiosensitizers and, 697-698
 radiosurgery v surgery in, 696-697
 radiotherapy recursive partitioning analysis and, 694
 stereotactic radiosurgery in, 695-696
 surgical resection for, 694-695
 therapy comparisons in, 695
 whole-brain radiotherapy and, 694, 706

- Brain tumor
 - biopsy in, 660
 - computer-assisted stereotactic resection in, 660
 - current issues in, 593-594
 - incidence of, 618, 659
 - language site identification in, 663
 - motor cortex identification in, 662-663
 - neuronavigation and, 660-661
 - preoperative imaging in, 659-660
 - prognosis in, and surgery, 663-664
 - stimulation mapping and, 661-662
 - subcortical pathway identification in, 662-663
- Breast, lymphatic drainage of, 345-346
- Breast cancer
 - adjuvant chemotherapy in, 240-242
 - adjuvant polychemotherapy in, 241
 - adjuvant radiation therapy in, 238-239
 - adjuvant therapy in, for women over 70, 242
 - axillary assessment in, 238
 - comorbidity in, 236-237
 - at diagnosis, by age, 235
 - in elderly, 234-235
 - female, cross-national mortality due to, 131
 - life expectancy and, 236-237
 - local management of, 237-239
 - location of, 345
 - lymphatic mapping and, 334-336
 - lymphoscintigraphy method for, 341
 - massage of, 326
 - metastatic, therapy for, in elderly, 243
 - micrometastasis in, 315-316
 - mortality from, 235
 - operative risks in, for elderly, 176-178
 - radioimmunotherapy in, 72-73
 - sentinel lymph node technique in, 298-302
 - sentinel nodes in, 345
 - screening recommendations for, in elderly, 235
 - systemic therapy for, in elderly, 239-242
 - therapy for, in postmenopausal women, 236-237
 - tumor biology of, in elderly, 235-236
 - tumor progression in, and aging, 144
- Breast-conserving therapy, in elderly, 177-178
- Breast implant, lymphatic mapping and, 329
- Breast reduction mammoplasty, lymphatic mapping and, 329-330
- Breslow thickness, 366
- Breslow's principle, 359
- Bromodeoxyuridine, 697
- Bronchoscopy, in esophageal cancer, 518
- Bryostatins-1, 758
- Busulfan, anti-T-lymphocyte globulin, cyclosporine A, fludarabine regimen, 11
- Busulfan, anti-T-lymphocyte globulin, cyclosporine A, fludarabine, cyclophosphamide regimen, 8
- C-MYC, 96
- C225, 737, 738
- CAD, 93
- Cag island, 454
- Calvert and Chatelut formulae, 162
- Campath-1H, 85-87
- Cancer
 - ageism and, 125-127
 - aging and, 265
 - comorbidity and, 156
 - elderly survival in, 125-127
 - end-of-life hydration in, 275-276
 - immune senescence and, 142
 - incidence of, in elderly, 128
 - increased incidence of, and aging, 128, 142-143
 - tumor progression in, and aging, 143-144
- Cancer, body mass index and, 456
- Cancer mortality
 - age distribution of, 133
 - comorbidity and, 153-155
 - competing risks in, and aging, 156-157
 - cross-national comparison of, 130-132
 - in US, 132-133
 - US age distribution of, 135
- Cancer patients, comorbidity in, 153-157
- Capacity
 - competency versus, 284
 - definition of, 283-284
- Capecitabine, in elderly, 167
- Carbogen, 806
- Carboplatin, 824
 - dosing of, in renal dysfunction, 163
 - in elderly, 166
 - in recurrent head and neck cancer, 810
- Carboplatin, mitomycin, fluorouracil regimen, 577
- Carboplatin, paclitaxel regimen, in esophageal cancer, 577
- Carboplatin, vinblastine regimen, in esophageal cancer, 577
- Carcinogenesis, interpretations of, 142-143
- Cardia adenocarcinoma
 - chromosomal alterations in, 481
 - classification of, 444-445
 - genetic changes in, 483
 - incidence of, 451-452
 - nomenclature of, 444-445
 - overview of, 444
- Cardia carcinoma
 - distribution of, 453
 - epidemiologic similarities of, 457
 - macroscopic appearance of, 466
 - Siewert classification of, 444-445
- Carmustine, dosing of, in renal dysfunction, 163
- Carmustine, dexamethasone, etoposide, cytarabine, melphalan regimen, 28
- Carmustine, etoposide, cytarabine, melphalan regimen, 28
- Carroll depression scale, 152
- Caspase-9, 95
 - activity of, 93-94
- Categorically needy, definition of, 289
- Catenin complex, 479-480
- Cathepsin B, 480
- Caucasian race, upper gastrointestinal malignancies and, 457
- CC 5013, 630
- CCI-779, 630, 641
- CCNU
 - for malignant glioma, 627
 - for oligodendroglioma, 649
- CD45, 75, 76
- CD52, 75
- CD95, 94, 98, 102, 103, 104
- CDKN1B, 478
- CDKN2A, 477-478
- Cefitinib, in recurrent head and neck cancer, 812
- Celecoxib, 630, 641
- Center for Epidemiologic Studies-Depression Scale, 152
- Central nervous system, radioimmunotherapy of, 71-72
- Cervical cancer, 394-397
- Cetuximab, in recurrent head and neck cancer, 812
- Chang classification, 669
- Charlson index, 155-156
- Chemical shift imaging, 606-607
 - lactate-edited three-dimensional, 611, 612
- Chemoprevention, definition of, 769
- Chemoradiation
 - in head and neck cancer, 781-782
 - in localized esophageal cancer, 557-559
 - in localized gastric cancer, 569

- Chemoradiation (*Continued*)
 postoperative, 788-789
 preoperative, in localized esophageal cancer, 559-561
 quality of life following, 830-832
 radiation dose intensification in, 558-559
 sequential, in head and neck cancer, 782-783
 in unresectable head and neck cancer, 787-788
- Chemotherapy
 adjuvant, *see* Adjuvant chemotherapy
 aging and, 160
 combination, for gastroesophageal malignancies, 579
 for gastroesophageal malignancies, 579
 for glioblastoma multiforme, 637-639
 induction, in head and neck cancer, 779-781
 in localized esophageal cancer, 556-557
 neoadjuvant, and lymphatic mapping, 330-331
 oral, in elderly, 167
 palliative, in head and neck cancer, 816-817
 in recurrent glioblastoma multiforme, 640
 reirradiation with, 817-819
 up-front, for oligodendroglioma, 650-651
 Children's Oncology Group, 682
- Chimerism, 12, 50
 incomplete, 42
 microsatellite marker analysis of, 78
 mixed, 56-57
- Choline, 607-608
- Chromosomal abnormalities, esophageal adenocarcinoma and, 480
- Chromosomal region 9p21, 718-719
- Chromosome 17p, 598
- Chromosome Y, loss of, 477
- Chronic myeloid leukemia
 age-specific incidence rates of, 188
 survival rates in, by age, 194
- Cilengitide, 630
- Cisplatin, 567, 798, 799, 818
 dosing of, in renal dysfunction, 163
 in bladder cancer, 254
 in elderly, 166
 in recurrent head and neck cancer, 809-812
- Cisplatin, cytarabine, fludarabine regimen, 23
- Cisplatin, docetaxel, fluorouracil regimen, 568, 579
- Cisplatin, docetaxel regimen, 568, 581
- Cisplatin, epirubicin, fluorouracil regimen, 578, 579-580
- Cisplatin, epirubicin, raltitrexed regimen, 576
- Cisplatin, etoposide, doxorubicin regimen, 578
- Cisplatin, etoposide, epirubicin regimen, 579
- Cisplatin, etoposide, fluorouracil, folinic acid regimen, 576
- Cisplatin, etoposide regimen, 576
- Cisplatin, fluorouracil regimen, 779-780, 576, 579
- Cisplatin, fluorouracil, epirubicin regimen, 579
- Cisplatin, irinotecan regimen, 568, 576, 581
- Cisplatin, paclitaxel, fluorouracil regimen, 576, 581
- Cisplatin, paclitaxel regimen, 576
- Cisplatin, vinorelbine regimen, 576
- Cis-retinoic acid, 630
- Cl-1033, 600, 601, 737, 740
- Cladribine, 14
- Clark level, 366, 417-418
- Clock drawing test, 151
- Clonal myeloid disease
 aging and, 186
 definitions of, 185-186
- Cobalt 57, 298-299
- Cochran's method, 359
- Cockayne's syndrome, 139
- Cognitive function assessment of, in elderly, 151
- COL-3, 630
- Collimator, high-resolution, 340
- Colloid particles, filtered v unfiltered, 327
- Colon cancer
 cross-national mortality due to, 131
 tumor progression in, and aging, 144
- Colorectal cancer
 adjuvant therapy of, 209-211
 chemotherapy for, by age, 210
 incidence of, by age, 206-207
 male v female incidence of, 134
 operative therapy for, 209
 operative treatment of, in elderly, 178-180
 screening for, 208-209
 treatment of, in elderly, 211
 US profile of, 134, 374-375, 403
- Community care, 289
- Comorbidity index, 155
- Competency
 capacity versus, 284
 definition of, 283
- Complete lymph node dissection, following positive sentinel lymph node biopsy, 365-369
- Comprehensive geriatric assessment, 149
- Computed tomography, in esophageal cancer, 517-518
 multidetector, 531
 spiral, 530-531
- Computer-assisted stereotactic resection, 660
- Conditioning
 conventional, v pattern of engraftment, 10
 reduced-intensity, *see* Reduced-intensity conditioning
 Continuous care facilities, 290
- Corticosteroids, for primary CNS lymphoma, 684-685
- COX-1, 759
- COX-2, 759
 inhibitors of, 774
- Cranial irradiation, prophylactic, 704-706
- Creatine, in brain tumor, 608
- CT, *see* Computed tomography
- Cumulative Illness Rating Scale-Geriatrics, 156
- Curcumin, 774-775
- Custodial care, 291
- Cyclin, 476
- Cyclin D1, 476-478, 758-759
- Cyclin E, 477, 478
- Cyclin-dependent kinase, 476
 inhibition of, 108
- Cyclooxygenase-2, inhibition of, 459
- Cyclophosphamide, busulfan regimen, 8
- Cyclophosphamide, etoposide, prednisone, vincristine, doxorubicin regimen, 42-43
- Cyclophosphamide, fludarabine regimen, 15
- Cyclophosphamide, fludarabine, granulocyte colony-stimulating factor, cyclosporine regimen, 50, 52
- Cyclophosphamide, rituximab, fludarabine regimen, 23
- Cyclophosphamide, total-body irradiation regimen, 8
- Cyclosporine A, 8
- Cyclosporine A, cyclophosphamide, fludarabine, granulocyte colony-stimulating factor regimen, 50, 52
- Cyclosporine A, mycophenolate mofetil regimen, 15
- CYP3A4 enzyme, 161
- Cyt c, 95
- Cytarabine, carmustine, etoposide, melphalan regimen, 28
- Cytarabine, cisplatin, fludarabine regimen, 23
- Cytarabine, dexamethasone, carmustine, etoposide, melphalan regimen, 28
- Cytarabine, dexamethasone regimen, high-dose, 28
- Cytarabine, dosing of, in renal dysfunction, 163
- Cytochrome P450, 161
- Cytokine storm, 60

- D1 dissection, in gastric cancer, 544
 D2 dissection, in gastric cancer, 544
 Daunorubicin, in elderly, 164-165
 Denmark, elderly population segment in, 129-130
 Depression
 in elderly, 151-152
 end-of-life, 276
 Dexamethasone, 28
 Dexamethasone, carmustine, etoposide, cytarabine, melphalan regimen, 28
 Dexamethasone, high-dose cytarabine regimen, 28
 DHAP protocol, 28
 Diet
 head and neck cancer and, 730
 upper gastrointestinal malignancies and, 457
 Diffuse large cell lymphoma, survival in, 25
 Diffuse type carcinoma, 473
 Diploid, 720
 Disability, definition of, 287-288
 DNA array analysis, in gastric cancer, 473
 DNA methylation, inhibition of, 108
 DNA repair theory, 139, 140
 Do-not-resuscitate order, 277-278
 Docetaxel, 567
 in elderly, 165-166
 in gastric cancer, 580-581
 in recurrent head and neck cancer, 810, 813, 811
 Docetaxel, cisplatin, fluorouracil regimen, 568, 579
 Docetaxel, cisplatin regimen, 568, 581
 Docetaxel, irinotecan regimen, in esophageal cancer, 577
 Donor, matched unrelated v HLA-matched sibling, 12
 Donor lymphocyte infusion, 22
 allogeneic, 4
 graft augmentation of, 61-64
 for overt relapse post-stem cell transplantation, 6-7
 for relapse prevention, 7-9
 Donor Th2 cell, 59
 in vitro generation of, 62
 Donor Th2 cell graft augmentation, 60-61
 Doxorubicin, 567
 in elderly, 164-165
 liposome-, 165
 Doxorubicin, etoposide, cisplatin regimen, 578
 Doxorubicin, etoposide, prednisone, vincristine, cyclophosphamide regimen, 42-43
 Doxorubicin, fluorouracil, methotrexate regimen, 578
 Doxorubicin, fluorouracil, mitomycin regimen, 578
 Doxorubicin, mechlorethamine, vinblastine, vincristine, bleomycin, etoposide, prednisone, granulocyte colony-stimulating factor regimen, 27
 Drug pharmacokinetics, in elderly, 160-162
 Drug resistance, 102-104
 DTIC, dosing of, in renal dysfunction, 163
 Ductal carcinoma-in-situ, lymphatic mapping and, 329
 Dysplasia
 in Barrett's esophagus, macroscopic appearance of, 466
 definition of, 469
 esophageal glandular, 470-471
 esophageal squamous cell, 470
 genetic changes in, 477
 histological features of, 469-479
 in stomach, 471
 E-cadherin, 479-480, 483
 E-cadherin gene mutation, 494
 E1A, 96
 E2F1, 96
 Echo time, 607
 long, 609, 610
 short, 608
 EF5, 805
 Effective dose
 for emission, 300
 patient, assessment of, 299-300
 in sentinel lymph node lymphoscintigraphy, 298
 for transmission, 299
 EKB-569, 601
 Elder law
 definition of, 282
 identifying client in, 283
 Elderly
 advanced directives and, 277-278
 ageism and, 125-127
 cancer care in, and ageism, 125-127
 cancer incidence in, 128
 comorbid disease in, 153-157
 cross-national comparison of, 129-130
 drug pharmacokinetics in, 160-162
 end-of-life depression in, 276
 end-of-life hydration in, 275-276
 end-of-life pain in, 274-275
 medical conditions in, 150-153
 treatment preferences of, 278
 US cancer profile in, 134
 Elderly abuse, 291-292
 Elective lymph node dissection, 369
 EMD 121974, 630, 641
 EMD 72000, 737, 738
 Endometrial cancer, 397-398
 Endoscopic mucosal resection, 508-509
 Endoscopic mucosal resection-C, 508
 Endoscopic mucosal resection-L, 508-509
 Endoscopic screening, esophageal adenocarcinoma and, 458-459
 Endoscopic ultrasonography
 in esophageal cancer, 517-518
 in esophageal cancer staging, 531-532
 in gastric cancer, 521
 for regional lymph node involvement, 535-536
 Endoscopy, esophageal squamous cell carcinoma and, 489
 Epidermal growth factor, 478, 583
 Epidermal growth factor receptor, 97, 478, 596-597, 601, 734
 inhibitors of, 737
 ligands of, 735
 overexpression of, 736
 signal transduction by, 735
 wildtype v mutant, 737
 Epigallocatechin gallate, 774-775
 Epirubicin, 567, 798
 in elderly, 165
 Epirubicin, cisplatin, fluorouracil regimen, 578, 580
 Epirubicin, cisplatin, raltitrexed regimen, 576
 Epirubicin, etoposide, cisplatin regimen, 579
 Epithelial-cell adhesion molecule, 72
 EPOCH, fludarabine regimen, 59
 EPOCH regimen, 42-43
 Epstein-Barr virus, head and neck cancer and, 728-729
 ErbB1, 478
 ErbB2, 478
 in medulloblastoma, 668
 Erbitux, 737, 738
 Erlotinib, 630
 Error catastrophe theory, 139, 140
 Esophageal adenocarcinoma
 aneuploidy and, 480
 Barrett's esophagus and, 490
 carcinogenesis pathways for, 454
 chromosomal alterations in, 481
 distribution of, 453
 epidemiologic similarities of, with other malignancies, 457

- Esophageal adenocarcinoma (*Continued*)
 epidemiology of, 490
 genetic changes in, 477
 incidence of, 451, 452, 476
 microsatellite instability and, 480
 molecular aberrations in, 472-473
 natural history of, 491
 obesity and, 456
 risk factors for, 490-491
 screening for, 491-492, 493
 staging of, 515-516
- Esophageal cancer
 by age, 207
 age-adjusted incidence in, 451
 biological differences in, 446-447
 cisplatin-based chemotherapy in, 576
 diet and, 455-456
 distant metastases detection in, 533-535
 endoscopic ultrasonography staging in, 531-532
 histological typing of, 466-468
 imaging in, 517-518
 incidence of, 487, 574
 international distribution of, 452
 localization of, 465
 localized, *see* Localized esophageal cancer
 long-term survival in, 549-550
 lymphatic mapping for, 409-410
 metastatic, chemotherapy in, 574-577
 multidetector CT in, 521
 new developments in, 552
 non-cisplatin-based chemotherapy in, 577
 overview of, 441-443
 pathologic considerations in, 450-451
 patient aging and, 213-214
 PET in, 532, 533
 PET response assessment in, 536-538
 prevention of, 456-459
 resection in, survival following, 549
 risk factors for, 453-456
 sentinel node concept in, 410
 Siewert classification of, 444-445
 spiral CT in, 530-531
 staging of, 447-448, 469
 survival and, 453
 TNM staging of, 514
 tumor spread in, 468-469
- Esophageal glandular dysplasia, 470-471
- Esophageal squamous cell carcinoma, 480-482
 alcohol consumption and, 455
 chromosomal alterations in, 481
 distribution of, 452-453
 epidemiologic similarities of, with other malignancies, 457
 incidence of, 451, 452
 macroscopic appearance of, 466
 molecular aberrations in, 472
 natural history of, 487
 risk factors for, 488
 screening for, 487-488
 staging of, 515-516
 tobacco smoking and, 455
- Esophageal squamous cell dysplasia, 470
- Esophagectomy
 complications following, 551
 survival following, 551-552
 transthoracic v transhiatal, 550-552
- Esophagogastric cancer
 prevention of, 507-508
 treatment knife in, 509
 treatment of, 508-509
- Esophagogastric cancer (*Continued*)
 Esophagogastric lesion, premalignant, *see* Premalignant esophagogastric lesion
- Esophagogram, double-contrast barium, in gastric cancer, 524, 525
- Esophagus
 adenocarcinoma of, 444-445
 small cell carcinoma of, 471
 squamous cell carcinoma of, 466-467
- Essential person, definition of, 288
- Etoposide, in elderly, 166-167
- Etoposide, carmustine, cytarabine, melphalan regimen, 28
- Etoposide, cisplatin regimen, 576
- Etoposide, cisplatin, fluorouracil, folinic acid regimen, 576
- Etoposide, dexamethasone, carmustine, cytarabine, melphalan regimen, 28
- Etoposide, doxorubicin, cisplatin regimen, 578
- Etoposide, epirubicin, cisplatin regimen, 579
- Etoposide, folinic acid, fluorouracil regimen, 578
- Etoposide, mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, prednisone, granulocyte colony-stimulating factor regimen, 27
- Etoposide, mitomycin regimen, 577
- Ex vivo lymphatic mapping, in colorectal cancer, 406-407
- Ex vivo mapping technique, 377
- Ex vivo ratio, 363
- Exfoliative balloon cytology, esophageal carcinoma and, 488-489
- Familial cancer, aging and, 264
- Fas, 479
- Fat clearance technique, 404
- Fenretinide, 630
- Fibroblast growth factor, 760-761
- Fiduciary relationship, definition of, 283
- Field cancerization, 735-736, 769-770
- Field carcinogenesis, 264-266
- Filgrastim, 24, 43
- Flavopiridol, 582-583, 758
- Florida melanoma trial, 363-369
 study design of, 369
- FLT3 mutation, 189-190
- Fludarabine, 10-11, 14, 42
 dosing of, in renal dysfunction, 163-164
 in elderly, 163
- Fludarabine, busulfan, anti-T-lymphocyte globulin, cyclosporine A regimen, 11
- Fludarabine, cyclophosphamide, granulocyte colony-stimulating factor, cyclosporine regimen, 50, 52
- Fludarabine, cyclophosphamide regimen, 15
- Fludarabine, cyclophosphamide, rituximab regimen, 23
- Fludarabine, cytarabine, cisplatin regimen, 23
- Fluorescein, 378
- Fluorescent in situ hybridization, 600
- Fluoropyrimidine, oxaliplatin regimen, 581-582
- Fluorouracil, 104, 567, 799, 818, 819
 in elderly, 162-163
 in recurrent head and neck cancer, 809-810
 toxicity of, in elderly, 163
- Fluorouracil, carboplatin, mitomycin regimen, 577
- Fluorouracil, cisplatin regimen, 576, 579, 779-780
- Fluorouracil, cisplatin, etoposide, folinic acid regimen, 576
- Fluorouracil, cisplatin, paclitaxel regimen, 576
- Fluorouracil, docetaxel, cisplatin regimen, 568, 579
- Fluorouracil, doxorubicin, methotrexate regimen, 578
- Fluorouracil, doxorubicin, mitomycin regimen, 578
- Fluorouracil, epirubicin, cisplatin regimen, 578, 579-580
- Fluorouracil, etoposide, folinic acid regimen, 578
- Fluorouracil, irinotecan, folinic acid regimen, 568
- Fluorouracil, paclitaxel, cisplatin regimen, 581
- Folinic acid, cisplatin, etoposide, fluorouracil regimen, 576
- Folinic acid, etoposide, fluorouracil regimen, 578

- Folinic acid, irinotecan, fluorouracil regimen, 568
Folstein Mini-mental state Examination, 151
Folypolyglutamate synthase, 102-103
Forkhead transcription factors, 97
France, elderly population segment in, 129-130
Fransnod study, 305, 308
Free radical damage theory, 139, 140
Free radical hypothesis, 139, 140
French Society for Pediatric Oncology, 682
Fresenius AG, 10
Fruits, upper gastrointestinal malignancies and, 457
Function, assessment of, 152
- Gait, in elderly, 151
Gallbladder cancer, aging and, 214
Gamma probe, 410
Gastrectomy, D1 v D2, in localized gastric cancer, 566-567
Gastric adenocarcinoma, 482-483
 chromosomal alterations in, 481
 epidemiology of, 446
 international distribution of, 452
 precursors of, 471
 WHO classification of, 467-468
Gastric body tumor, 521
Gastric cancer
 operative treatment of, in elderly, 181-182
 patient aging and, 213
Gastric cancer
 age-adjusted incidence in, 451
 biological differences in, 446-447
 carcinogenesis pathways for, 454
 clinical staging in, 520
 CT in, 520
 D1 dissection in, 545
 D2 dissection in, 545-546
 distal, 542-546
 distribution of, 453
 early, 548
 endoscopic ultrasonography in, 520-524
 endoscopic ultrasonography staging in, 531-532
 epidemiology of, 493
 following D1 and D2 dissection, 546
 gene expression profiles in, 473-474
 genetic screening for, 493-494
 Helicobacter pylori infection and, 453-454
 hepatic metastases of, 521
 histological typing of, 466-468
 incidence of, 574
 intestinal reconstruction in, 547-548
 intraperitoneal therapy in, 570
 localized, see Localized gastric cancer
 lymphatic mapping in, 411-412
 macroscopic appearance of, 465-466
 metastatic, treatment of, 577-582
 multidetector CT in, 531
 overview of, 441-443
 p53 and, 473
 palliative chemotherapy in, 578
 palliative surgery in, 547
 palliative treatment in, 548
 pancreatosplicectomy in, 546
 pathologic considerations in, 450-451
 pathologic staging in, 518-520
 predisposing conditions for, 493
 risk factors for, 493
 salty food and, 456
 screening for, 493
 screening markers for, 494
- Gastric cancer (Continued)
 screening recommendations for, 494
 sentinel lymph node biopsy in, 524
 sentinel node concept in, 412
 Siewert classification of, 444-445
 smoking and, 455
 staging of, 447-448, 470
 stomach resection in, 546-547
 survival and, 453
 two-year survival in, 571
Gastric carcinoma
 macroscopic appearance of, 466
 rare types of, 468
 TNM classification of, 519
 types of, 473
Gastric cardia adenocarcinoma
 chromosomal alterations in, 481
 classification of, 444-445
 incidence of, 451-452
 nomenclature of, 444-445
 overview of, 444
Gastric cardia carcinoma
 distribution of, 453
 epidemiologic similarities of, 457
 macroscopic appearance of, 466
 Siewert classification of, 444-445
Gastric noncardia carcinoma, 457
Gastroesophageal junction
 cancers at, 524-526
 resection in, survival following, 549
Gastroesophageal junction adenocarcinoma
 biological differences in, 446
 classification of, 444-445
 clinical differences of, and staging, 447-448
 cytogenetic studies in, 447
 epidemiology of, 445-446
 incidence of, 451
 nodal metastases of, and site involved, 448
 nomenclature of, 444-445
 overview of, 444
 pathologic considerations in, 450-451
 Siewert classification of, 444-445, 515
 treatment of, 448-449
Gastroesophageal junction carcinoma, 548-549
 macroscopic appearance of, 466
 precursors of, 471
 staging of, 470
Gastroesophageal reflux disease
 Barrett's esophagus and, 454-455
 laryngeal cancer and, 729-730
 premalignant esophagogastric lesions and, 501
 upper gastrointestinal malignancies and, 457
Gastrointestinal cancer, skip metastasis in, 409
Gastrointestinal system, radioimmunotherapy of, 72
Gastrosocopy, premalignant esophagogastric lesions and, 505-506
Gefitinib, 630, 641, 774
Gemcitabine
 in elderly, 162
 in recurrent head and neck cancer, 811, 811
Gender, upper gastrointestinal malignancies and, 457
Gene expression profiling, 109-110
Genetic changes, in adenocarcinoma, 477
Geographic location, upper gastrointestinal malignancies and, 457
GERD, see Gastroesophageal reflux: disease
Geriatric assessment
 importance of, 149-150
 multidimensional screening instrument for, 154
Geriatric Depression Scale, 152
Geriatric syndromes, 150-153

- Germ cell tumor(s)
 clinical symptoms of, 677-678
 histological classification of, 676-677
 incidence of, 676
 intracranial, phase II-III studies of, 681-682
 nongerminomatous, 680-681
 radiological findings in, 678
 signs of, 677-678
 sites of, 677
 survival following, and histology, 680
 therapeutic classification of, 680
 tumor markers in, 678-679
- German Clinical Interdisciplinary Sentinel study, 305, 307
- Germinoma, 679-680
 neurohypophyseal, 677
 radiological findings in, 678
- Gleevec, 598, 630
- Glial tumor, noninvasive diagnosis of, 612-613
- Glioblastoma multiforme, 612
 adjuvant chemotherapy for, 637
 bilateral, 638
 chemotherapy for, 637-639
 clinical research in, 640-641
 incidence of, 635
 presentation of, 635-636
 radiation for, 637
 recurrent, management of, 639-640
 response rates in, 638
 signal transduction inhibitors in, 641
 supportive care in, 641
 surgery for, 636-637
 survival following, 640
 treatment challenges of, 636
 trial designs in, 641
- Glioma
 definition of, 595
 high-grade, 610
 low-grade, *see* Low-grade glioma
 malignant, *see* Malignant glioma
 radiotherapy and, 706-708
 radiotherapy neurotoxicity and, 707
 signaling pathways in, 596
 therapeutic planning for, 613-614
- Gliosis, radiation-induced, 614
- Glutamate, in brain tumor, 611-612
- Glutamine, in brain tumor, 611-612
- Glutathione-S-transferase M1 null genotype, 447
- Glycation, 140
- Goldman criteria, for postoperative cardiac complications, 176
- Goldman risk categories, 177
- Graft rejection
 prevention of, 63
 T-cell immunity and, 56-57
- Graft-versus-Hodgkin's disease effect, 30-31
- Graft-versus-host disease, 57-58, 85-87
 as type I immune response, 60
 incidence of, 25
 prophylaxis of, 24
- Graft-versus-leukemia effects, 4
 in different disease categories, 8
- Graft-versus-lymphoma effects, 22
- Graft-versus-malignancy effects, following allogeneic bone marrow transplantation, 47-48
- Graft-versus-renal cell carcinoma effects, 51-52
- Graft-versus-tumor effects, 33-34, 39, 48
 renal cell carcinoma and, 49-51
- Granulocyte colony-stimulating factor, 760-761
 cyclophosphamide, fludarabine, cyclosporine regimen, 50, 52
- Granulocyte colony-stimulating factor, mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, prednisone regimen, 27
- Granulocyte-macrophage colony-stimulating factor, 37-38, 760-761
- Guardianship, 284-285
- GW572016, 737, 740
- H-R3, 737, 738
- HCG, germ cell tumors and, 678-679
- Head and neck
 lymph drainage patterns in, 385
 lymphatic drainage of, 343
- Head and neck cancer
 chemopreventive agents in, 772
 chemoradiation v induction chemotherapy in, 790
 diagnosis of, and human papillomavirus, 750-751
 in elderly, 227-229
 human papillomavirus in, 745-746
 induction chemotherapy in, 779-781
 induction chemotherapy plus chemoradiation in, 790-791
 organ preservation in, 779-780
 pathogenesis in, 746-748
 patient priorities in, 832-833
 premalignant progression to, 735-736
 preoperative lymphoscintigraphy in, 383-385
 prognostic significance in, of human papillomavirus, 748-749
 reirradiation in, 817
 risk factors for, and human papillomavirus, 748-750
 treatment late effects in, 828
 unresectable patients with, 780
- Head and neck malignancy, esophageal squamous cell carcinoma and, 488
- Head and neck squamous cell carcinoma
 clinical progression of, 719
 early detection in, 721
 histopathology progression of, 719
 incidence of, 718, 726-727
 molecular diagnosis in, 721-722
 molecular diagnostics for, 720-721
 molecular progression model of, 718-719
 mortality from, 727
 prevalence of, 727
 tobacco exposure and, 727-728
- Health care proxy, 285
- Hearing impairment, in elderly, 150
- Helicobacter pylori*, eradication of, 457-458
- Helicobacter pylori* infection, 508
 gastric cancer and, 453-454
 premalignant esophagogastric lesions and, 501
 upper gastrointestinal malignancies and, 457
- Hematologic malignancies, radioimmunotherapy in, 73
- Hematoxylin and eosin analysis, 312-313, 324-325
- Hepatic metastases, of gastric cancer, 521
- Hepatocellular carcinoma, aging and, 214
- Hepatocyte growth factor, 760-761
- High-dose therapy, in Hodgkin's disease, 28
- Histone deacetylase, inhibition of, 108
- HMB 45, 357, 358
- Hodgkin's disease
 autologous stem cell transplantation in, 28
 conventional salvage therapy in, 27-28
 in elderly, 202
 high-dose therapy in, 28
 radioimmunotherapy in, 74-75
 staging for, 201
 survival in, 29-30
- Home care, 290
- Hospice
 definition of, 287
 for terminally ill elderly, 278-279
- Hot spot, 339

- Hsp70, 100
Human antimouse antibodies, 68, 74
Human papillomavirus
 in head and neck cancer, 728-729, 745-746
 in premalignant lesions, 748
Human papillomavirus infection, esophageal carcinoma and, 488
Hutchinson-Guilford syndrome, 139
Hydration, end-of-life, 275-276
Hydroxyurea, 818, 819
 dosing of, in renal dysfunction, 163
 in elderly, 168
Hyperbaric oxygen therapy, 806
Hypermethylation, 483
Hypoxia, detection of, 805
Hypoxia-inducible factor 1 alpha, 760
- IAP family, 95, 99
IAP proteins, 99
IASPP, 104
IBCSG 23-01, 305-306, 308-309
Idarubicin, in elderly, 165
Idiotypic, 37
Idiotypic vaccination, 40-41
Ifosfomide, dosing of, in renal dysfunction, 163
Imatinib, 107-108, 582
Imatinib mesylate, 598, 601, 630
Immune senescence, cancer and, 142
Immune theory, 139, 141
Immunity, aging and, 141-142
Immunoablative, 59
Immunoglobulin receptor, 37
Immunohistochemical staining, 404
Immunohistochemistry, 313
Immunosuppression, 14
Immunosuppressive therapy, 24
Immunotherapy, allogeneic, in solid tumors, 48
Immunotoxin, synthesis of, 739
In vivo lymphatic mapping, in colorectal cancer, 405-406
In vivo mapping technique, 375-377
Index of Coexistent Disease, 156
Informed consent, 284
Initiation, definition of, 770
Injection technique, 326-328
Insulated tip knife, 509
Insulin-like growth factor, 760-761
Insurance, Medigap, 287
Interferon, 60
Interferon alfa, adjuvant, for resected stage III melanoma, 364-365
Interleukin, 60, 760-761
Internal mammary node dissection, 328
International Breast Cancer Study Group trial 23-01, 305-306, 308-309
International CNS Germ Cell Tumor Study Group, 681-682
International Commission on Radiological Protection, 299
International Prognostic Index, for non-Hodgkin's lymphoma, 201
International Society of Pediatric Hematology and Oncology, 682
Interstitial brachytherapy, 626
Interval node, 344-345
Intestinal carcinoma, macroscopic appearance of, 466
Intestinal marker, 476
Intestinal type carcinoma, 473
Intradermal technique, 327
Intraparenchymal technique, 327
Intrinsic mutagenesis theory, 139-140
Iodine 131, 70
Ionizing radiation theory, 139, 141
Iressa, 630, 737, 739-740
Irinotecan
 in elderly, 164
 in gastric cancer, 580-581
 irinotecan, cisplatin regimen, 568, 576, 581
 irinotecan, docetaxel regimen, in esophageal cancer, 577
 irinotecan, folinic acid, fluorouracil regimen, 568
 isolated tumor cells, 311
 isotretinoin, 772-773
 isotretinoin, 630
 Israel, minitransplants in, 2
 Italy, elderly population segment in, 129-130
- Japan, elderly population segment in, 129-130
Japanese classification, 504
Japanese Pediatric Brain Study Group, 681
Judge, role of, in medical treatment, 285
- Kaplan-Feinstein index, 156
Kennedy, MD, Byrl James, 124
Kernohan schema, 620
Keyhole limpet hemocyanin, 38
Kinase, cyclin-dependent, 476
KiSS study, 305, 307
Knife
 in esophagogastric cancer treatment, 509
 insulated tip of, 509
- Lactate, in brain tumors, 610-611
Language site, identification of, 663
Laparoscopic technique, 377
Laparoscopic ultrasonography, for staging, in gastric cancer, 522, 523
Laparoscopy
 in esophageal cancer, 518
 for staging, in gastric cancer, 522
Laryngeal cancer
 gastroesophageal reflux and, 729-730
 incidence of, 726-727
Lauren's classification
 of adenocarcinoma, 467-468
 diffuse carcinoma according to, 466
 of stomach cancer, 503
Law
 charge-limit, 286
 creation of, 282
Leather bottle stomach, 466
Leukemia
 monoclonal antibody purging in, 83-84
 radioimmunotherapy in, 75
Life expectancy
 cross-national comparison of, 130-132
 disease-related mortality and, 157
 maximum survival versus, 137-138
Lifestyle modification, esophageal cancer and, 456-457
Lipid, in brain tumors, 611
Liposomal daunorubicin, in elderly, 165
Liposomal doxorubicin, in elderly, 165
Liver cancer, incidence of, by age, 207
Living will, 285
Localized esophageal cancer
 adjuvant radiation therapy in, 555
 chemoradiation in, 557-559, 561-562
 future directions in, 562
 optimal surgical procedure in, 554-555
 postoperative chemotherapy in, 557
 preoperative chemoradiation in, 559-561
 preoperative chemotherapy in, 556-557
 primary radiation therapy in, 555
 surgical resection in, 554
Localized gastric cancer
 adjuvant chemotherapy in, 567-569
 chemoradiation in, 569
 D1 v D2 gastrectomy in, 567
 neoadjuvant therapy in, 569-572

- Localized gastric cancer (*Continued*)
 postoperative adjuvant therapy in, 572
 primary curative treatment of, 566-567
- Long-term care, definition of, 289
- Long-term care facilities, for terminally ill elderly, 279-280
- Loss of heterozygosity, 718, 720
- Low-grade glioma, 604
 age in, and survival, 657, 658
 chemotherapy plus radiation for, 655-656
 clinical trials for, 656-658
 histology of, and survival, 656
 radiotherapy dosing for, 654-655
 radiotherapy timing for, 654
 surgical resection in, 655
 survival in, 655
 time to neurotoxicity in, 657
 tumor size of, and survival, 656
- Ludwig trial, 313
- Lung cancer
 cross-national mortality due to, 131
 male v female incidence of, 134
 tumor progression in, and aging, 144
 US profile of, 134
- Lutetium 177, 70
- LY294002, 600
- LY317615, 630
- Lye ingestion, 490
 esophageal squamous cell carcinoma and, 488
- Lymph drainage, 353-354
 of anterior trunk, 342-343
 of head and neck, 343-344
 of lower limb, 344
 of posterior trunk, 341-342
 previous radiotherapy and, 354
 previous surgery and, 354
 of skin, 341
 of upper limb, 344
- Lymph flow, physiology of, 338-339
- Lymph flow pattern, by breast quadrant, 347
- Lymph node, naming of, of stomach, 543
- Lymph node dissection
 for gastric cancer, 544
 therapeutic, 366
- Lymphadenectomy
 selective, 427
 three-field, 555
- Lymphatic lake, 345
- Lymphazurin, 377-378
 injection of, 376
- Lymphoid neoplasms, World Health Organization classification of, 200
- Lymphoma
 incidence of, and aging, 199
 treatment of, in elderly, 201-203
- Lymphoproliferative disorders, reduced post-transplant, 87
- Lymphoscintigram, 390
 of head, 384, 387
 low- v high-dose radiocolloids and, 389
- Lymphoscintigraphy
 for esophageal cancer, 410
 preoperative, in melanoma, 349-352
 preoperative anterior, 395
 of sentinel lymph node, patient effective dose in, 298-299
 timing preoperative, 352
- Lymphoscintigraphy method
 for breast cancer, 341
 for melanoma, 340-341
- Magnetic resonance imaging
 of brain tumors, 605
 FLAIR, 690
- Magnetic resonance imaging (*Continued*)
 intraoperative, 661
 of medulloblastoma, 667-668
- Magnetic resonance spectra, 607
- Magnetic resonance spectroscopy, of anaplastic astrocytoma, 618-619
- Male gender, upper gastrointestinal malignancies and, 457
- Malignant glioma
 adjuvant chemotherapy for, 627-628
 drug access in, 628-629
 monoclonal antibodies for, 627
 recurrent, chemotherapy for, 628
- Malnutrition, in elderly, 150
- Mantle cell lymphoma, survival in, 25
- Marijuana, head and neck cancer and, 730
- Marimastat, 630, 641
- Mastectomy, prophylactic, and lymphatic mapping, 329
- Mcl-1, 105
- Meat, preserved, upper gastrointestinal malignancies and, 457
- Mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, prednisone, granulocyte colony-stimulating factor regimen, 27
- Mechlorethamine, vincristine, procarbazine, prednisone regimen, 27
- Medicaid, 288-289
- Medical International Radiation Dose schema, 298
- Medically needy, definition of, 289
- Medicare + Choice, 287
- Medicare, definition of, 286
- Medicare Part C, 287
- Medigap insurance, 287
- Medulloblastoma
 average-risk, 671
 chemotherapy in, 671
 clinical presentation of, 666-667
 high-risk, 671
 incidence of, 666
 infant, 671-672
 light microscopy of, 668
 molecular genetics of, 668-669
 neuroimaging of, 667-668
 pathology of, 668
 radiation therapy in, 670
 relapsed, 672
 risk stratification in, 669-670
 staging of, 669
 surgery in, 670
 treatment sequelae in, 672-673
- Melan A, 357, 358
- Melanoma
 lymphatic mapping and, 333-334
 lymphoscintigraphy method for, 340-341
 molecular staging of, 365
 preoperative lymphoscintigraphy in, 349-352
 2002 American Joint Committee on Cancer staging of, 416-419
- Melphalan, 14
 dexamethasone, carmustine, etoposide, cytarabine regimen, 28
 dosing of, in renal dysfunction, 163
- Melphalan, carmustine, etoposide, cytarabine regimen, 28
- Merkel cell cancer, sentinel lymph node biopsy and, 391
- MET, 755-756
- Metastasis, skip, 409
- Metastat, 630, 641
- Methotrexate, 567, 799
 dosing of, in renal dysfunction, 163
 in elderly, 162
 high-dose, plus radiotherapy, in primary CNS lymphoma, 687-688
 in recurrent head and neck cancer, 811
 tacrolimus regimen, 24
- Methotrexate, fluorouracil, doxorubicin regimen, 578

- Micrometastasis
clinical significance of, 313-315
definition of, 311
detection of, 312-313
studies evaluating, 314
to other sites, 315
- Micromorphometry, S classification and, 358-359
- Microsatellite, 480
- Microscopic nodal tumor burden, 421-422
- Milan trial, 305, 307-308
- Mini-BEAM regimen, 28
- Minitransplant, rationale for, 2
- Misonidazole, 697
- Mitochondria
apoptosis and, 102
regulation of, 94-95
resensitizing, 106-107
stabilization of, 98-99
- Mitomycin, 567, 818
oral etoposide regimen, 577
uracil, tegafur regimen, 579
- Mitomycin, carboplatin, fluorouracil regimen, 577
- Mitomycin, fluorouracil, doxorubicin regimen, 578
- Mitoxantrone, in elderly, 165
- MMP, 102
- Mobility, in elderly, 151
- Monoclonal antibody(ies)
anti-epidermal growth factor receptor, 737-738
application of, 109
for malignant glioma, 627
in vitro purging with, 83-84
- Monoclonal antibody-streptavidin, 70
- MOPP regimen, 27
- Mortality, comorbidity and, 153-155
- Motexafin-gadolinium, 697-698
- Motor cortex, identification of, 662-663
- MTOR, 756-757
- MTOR inhibitor, 601
- Mucinous adenocarcinoma, 467-468
- Multicenter Selective Lymphadenectomy trial, 371-372
- Multiple myeloma
in elderly, 203-204
nonablative preparative regimens in, 34-35
nonmyeloablative reduced-intensity transplantation in, 33-35
radioimmunotherapy in, 75
stem cell transplantation in, 38-39
- Multiple primary malignancies
clinical consequences of, 271-272
definition of, 267
epidemiology of, and age, 268-270
prevalence of, at autopsy, 268
prostate cancer and, 270-271
registry experience with, 268-270
renal cell carcinoma and, 271
research implications of, 271
smoking-related, 270
- MYC, amplification of, 479
- MYCC, in medulloblastoma, 668
- Mycophenolate mofetil, 77
plus cyclosporine A, 15
- Myeloid neoplasm, World Health Organization classification of, 186
- Myeloma, treatment of, in elderly, 203-204
- Myo-inositol, in brain tumor, 612
- Myol, 612
- N classification, 418
- N-acetylaspartate, in brain tumors, 610
- Nasopharyngeal carcinoma
adjuvant chemotherapy in, 797-798
concurrent chemoradiation in, 789-800
- Nasopharyngeal carcinoma (*Continued*)
epidemiology in, 794-795
genetic changes in, 795-796
genetic features of, 796-797
neoadjuvant chemotherapy and concurrent chemoradiation in, 800
neoadjuvant chemotherapy in, 798-799
pathogenesis of, 797
- National Comprehensive Cancer Network staging guidelines, 516
- Neck, lymph node basins of, 383
- Necrosis, 623, 90
radiation-induced, 614
recurrent tumor and, 625
- Needle knife, 509
- Neural cell adhesion molecule, 72
- Neuroendocrine theory, 139, 141
- Neuroimaging, of medulloblastoma, 667-668
- Neuronavigation, 660-661
- Neurosurgery, intraoperative imaging in, 660-661
- Neurotoxicity
following low-grade glioma radiotherapy, 707
following prophylactic cranial irradiation, 705
- NIA-NCI Cancer and Comorbidity Index, 155-156
- Nicotinamide, 806
- Nitrosamines, esophageal carcinoma and, 488
- NK cell(s), 53, 60, 100
- Non-Hodgkin's lymphoma
in elderly, 202-203
International Prognostic Index for, 201
radioimmunotherapy in, 73-74
staging for, 201
- Non-small cell lung cancer
advanced, treatment of, 223-224
treatment of, and aging, 220-221
- Nonmyeloablative stem cell transplantation
experimental basis for, 5-6, 77-79
in hematologic malignancies, 9-15
immunoblastic, 58-60
for immunotherapy, of metastatic solid tumors, 15-17
mixed chimerism and, 56-57
in myeloma, 33-35
preparative regimens for, in lymphoma, 23
principles of, 5
rationale for, 1-2
regimens for, 23
renal cell carcinoma and, 50, 51
safer conditioning strategy in, 9
solid tumors and, 49, 52-53
strategies in, 10
- Nonsteroidal anti-inflammatory drugs, upper gastrointestinal malignancies
and, 459
- NSABP B-32, 429-430
- Nuclear factor B, 99-100
- Nursing home care, 291
- Nutrition
esophageal cancer and, 455
gastric cancer and, 456
- Nutrition Screening Initiative, 150
- Obesity, esophageal adenocarcinoma and, 456
- Ocular lymphoma
chemoradiotherapy complications in, 690-691
chemotherapy complications in, 690
radiotherapy complications in, 690
treatment of, 690
- Oligodendroglioma, 600
adjuvant chemotherapy for, 650
anaplastic, 611
chemotherapy for, 649-651
clinical presentation of, 646

- Oligodendroglioma, 600 (*Continued*)
 following chromosomal analysis, prognosis in, 647-648
 genetic lesions in, 647
 high-dose chemotherapy plus autologous bone marrow rescue for, 650
 overview of, 645
 pathology of, 646-647
 prognosis of, prior to chromosomal analysis, 647
 radiological presentation of, 646
 radiotherapy for, 648-649
 surgery for, 648
 treatment initiation in, 648
 up-front chemotherapy for, 650-651
- ONYX-015, 812
- Optical coherence tomography, 538-539
- Oral cavity, squamous cell carcinoma of, 387-390
- Oral premalignant lesion, 771-772
- Organ preservation, in head and neck cancer, 789-790
- OS1774, 601, 630, 641
- OS1-774, 737, 740
- Ovarian cancer
 radioimmunotherapy in, 72
 US profile of, 134
- Oxaliplatin, 581
 in elderly, 166
 fluoropyrimidine regimen, 581-582
- P13K, 96
- P16, 476-477, 759
- P16 tumor-suppressor gene, 596, 718-719
- P50 protein, 100
- P52 protein, 100
- P53, 101-102, 479, 759
 alterations in, 476, 477
 gastric cancer and, 473
 reintroduction of, 107
- P53 mutation, 189-190
- P53 pathway, 747
- P53 tumor-suppressor gene, 596, 598, 601, 719-720
- Paclitaxel, 818, 819
 in elderly, 165
 in gastric cancer, 580-581
 in recurrent head and neck cancer, 810, 813
- Paclitaxel, carboplatin regimen, in esophageal cancer, 577
- Paclitaxel, cisplatin, fluorouracil regimen, 578, 581
- Paclitaxel, cisplatin regimen, 576
- Pain, end-of-life, in cancer, 274-275
- Pain medication, toxicities of, in elderly, 275
- Palliative treatment, in gastric cancer, 548
- Palmaris tylosis, esophageal carcinoma and, 488
- Pancreatic cancer
 cross-national mortality due to, 131
 incidence of, by age, 207
 operative treatment of, in elderly, 180-181
 treatment of, and aging, 212-213
 US profile of, 134
- Pancreatosplenectomy, 546
- Papillary adenocarcinoma, 467-468
- Parotidectomy, 386
- Pathologic staging, definition of, 519
- Pathologist, cumulative radiation dose to, 302
- Patient compliance, oral chemotherapy and, 167
- PDGFR- α , in medulloblastoma, 668
- PDK1, 96
- PDK2, 96
- Perifosine, 758
- PET, *see* Positron emission tomography
- PF regimen, 779-781
- Pharmacokinetics, drug, and elderly, 160-162
- Phosphatase and tensin homologue, deleted on chromosome 10, 96-97
- Phosphocreatine, in brain tumor, 608-609
- PI-3 kinase pathway, 598-599, 601
- Pimonidazole, 805
- PKC, 756-758
- PKI-116, 601
- PKI-166, 737, 740
- PLAP, germ cell tumors and, 678-679
- Platelet-derived growth factor, 597-598, 601, 760-761
- Ploidy, 720
- Plummer-Vinson-Patterson Kelly syndromes, esophageal squamous cell carcinoma and, 488
- Point-resolved spectroscopy, 606-607
- Polypharmacy, in elderly, 151
- Population, elderly segment of, 128-129
- Positron emission tomography, 619
 CT v, 533-535
 in distant metastases detection, 533-535
 in esophageal cancer, 517-518, 532, 533
 in esophageal cancer pretherapeutic staging, 535
 in gastric cancer staging, 524
 for therapy response assessment, 536-538
- Power of attorney, 285
- PRb pathway, 747
- Prednisone, etoposide, vincristine, cyclophosphamide, doxorubicin regimen, 42-43
- Prednisone, mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, granulocyte colony-stimulating factor regimen, 27
- Prednisone, mechlorethamine, vincristine, procarbazine regimen, 27
- Premalignant esophagogastric lesion
 causal facts of, 500-502
 detection of, 505-507
 endoscopic appearance of, 503-505
 epithelium plasticity and, 500-501
 gastroscopy and, 505-506
 histopathological classification of, 499-500, 502-503
 Japanese classification and, 504
 prevention of, 507-508
 superficial, 503-504
 surveillance of, 509-510
 treatment of, 508-509
- Presbyopia, in elderly, 150
- Primary central nervous system lymphoma
 adjuvant chemotherapy for, 687
 biologic therapy for, 689
 chemotherapy alone for, 688-689
 chemotherapy for, 686-689
 corticosteroids for, 684-685
 high-dose methotrexate plus radiotherapy for, 687-688
 incidence of, 684
 radiotherapy for, 685-686
 radiotherapy neurotoxicity and, 708-709
 relapse therapy in, 689
 stem cell rescue for, 689
 surgery for, 685
 survival following, 686
 treatment outcomes in, 685
- Prinomastat, 641
- Procarbazine
 for malignant glioma, 627
 for oligodendroglioma, 649
- Procarbazine, mechlorethamine, vincristine, prednisone regimen, 27
- Program for All Inclusive Care for the Elderly, 290
- Progression, definition of, 770
- Promotion, definition of, 770
- Prophylactic cranial irradiation, 704-706
 neurotoxicity following, 705
- Prostate cancer
 chemotherapy in, 258-259
 cross-national mortality due to, 131

- Prostate cancer (*Continued*)
hormonal therapy in, 257-259
incidence of, 255
localized, 255-256
radiation therapy in, 257
radical prostatectomy in, of elderly, 256-257
tumor progression in, and aging, 144
US profile of, 134
watchful waiting in, of elderly, 256
- Prostate cancer, radioimmunotherapy in, 73
- Prostate-specific antigen, use of, 255
- Proteasome, 101, 759-760
inhibition of, 108-109
- Proton magnetic resonance spectroscopy, 605-606
basic principles of, 606-607
physics of, 606
spectral localization and, 606-607
- PS-341, 583, 630, 641
- PTCH gene, in medulloblastoma, 668-669
- PTEN, 96
- PTEN tumor-suppressor gene, 596, 599
- PTK787, 641
- Quality of life, criteria of, 827
- R115777, 630, 641
- RAD-001, 641
- Radiation
external-beam, dosage increase and, 559
for glioblastoma multiforme, 637
head and neck cancer and, 730
in recurrent glioblastoma multiforme, 640
- Radiation dose, intensification of, 558-559
- Radiation exposure
to pathologist, 302
personnel dose of, 301
to surgical team, 298-299
to technologist, 302
- Radiation therapy, in localized esophageal cancer, 555
- Radioactive specimen, handling of, 301-302
- Radiocolloid
low v high dose, 389
for lymphatic mapping, 319-320
selecting appropriate, 339-340
- Radiocolloid technique, 318, 326
- Radioenhancement, in head and neck cancer, 786-787
- Radioimmunoconjugate, 69
- Radioimmunotherapy
approaches to, 69-70
in breast cancer, 72-73
of central nervous system, 71-72
of gastrointestinal system, 72
in hematologic malignancies, 73
in Hodgkin's disease, 74-75
in leukemia, 75
in multiple myeloma, 75
in non-Hodgkin's lymphoma, 73-74
in ovarian cancer, 72
in prostate cancer, 73
in renal cancer, 73
of solid tumors, 71
- Radioisotope, choice of, 70-71
- Radionecrosis, 657
- Radionuclide
alpha-emitting, 70, 71, 77
beta-emitting, 70, 71, 77
in radioimmunotherapy, 70
- Radioresistance, in head and neck cancer, 786-787
- Radiosensitizer, 697-698
in head and neck cancer, 806
- Radiotherapy
accelerated fractionation and, 803
accelerated regimens of, 804
accelerated repopulation and, 803
acute toxicity of, 823-824
altered fractionation, 802, 804-805
in anaplastic astrocytoma, 624-625
brain tissue and, 702-704
cognitive sequelae of, 710
glioma and, 706-708
quality of life following, 828-830
repeat, 817-819
- Raf, 756-757
- Raltitrexed, cisplatin, epirubicin regimen, 576
- Ras, 756-757
- RAS family, 478-479
- RAS mutation, 189-190, 483
- Ras pathway, 598, 601
- Ras protein, 97
- RB tumor-suppressor gene, 596
- Receptor tyrosine kinase, 108
in medulloblastoma, 668
- Receptor tyrosine kinase neurotrophin-3 receptor, in medulloblastoma, 668
- Rectal cancer, localized, in elderly, 210-211
- Reduced-intensity conditioning
experimental basis for, 5-6
in hematologic malignancies, 9-15
in Hodgkin's disease, 29-30
improved safety of, 9
principles of, 5
rationale for, 1-2
strategies in, 10
- Reflux, prevention of, 458
- Renal cell carcinoma
graft-versus-tumor effect and, 49-51
incidence of, 259-260
radioimmunotherapy in, 73
tumor progression in, and aging, 144
- Renal dysfunction, chemotherapy dosing and, 163
- Replicative senescence, 138
- Retinoblastoma, 477
- Reverse-transcriptase polymerase chain reaction, 313, 324, 360, 365
- Rhenium 186, 70
- Rhenium 188, 70
- Ringertz schema, 620
- Rituximab, 84-85
- Rituximab, fludarabine, cyclophosphamide regimen, 23
- RNA interference, apoptosis and, 109
- Rothmund-Thomson syndrome, 139
- S classification, 358-359
- Salty food, gastric cancer and, 456
- Salvage therapy, conventional, 27-28
- Sargramostim, 37
- Satariano comorbidity index, 155-156
- SCH66336, 641
- Screening
for esophageal squamous cell carcinoma, 487-490
Japanese, and premalignant esophagogastric lesions, 505
- Seattle protocol, 507
- Self-neglect, 292
- Senescence
immune, and cancer, 142
replicative, 138
- Sentinel lymph node
in breast cancer, 345
definition of, 324, 339
naming of, 375
processing of, 357-358

- Sentinel lymph node (*Continued*)
 removal of, 328
 typical sites for, 355
- Sentinel lymph node biopsy, 304
 in breast cancer, 325
 in elderly, 178
 in favorable breast cancer, 322
 in gastric cancer, 524
 internal mammary, 321-322
 intraoperative lymphatic mapping and, 385-387
 in Merkel cell cancer, 391
 negative, axillary recurrence rate following, 320-321
 operative technique for, 354-355
 for oral cavity squamous cell carcinoma, 387-390
 in thyroid cancer, 390-391
- Sentinel lymph node concept
 in esophageal cancer, 410
 in gastric cancer, 412
- Sentinel lymph node dissection, clinical implications of, 428-429
- Sentinel lymph node lymphoscintigraphy, patient effective dose in, 298-299
- Sentinel lymph node mapping
 as breast cancer standard, 325
 breast implants and, 329
 clinical applications of, 410-413
 discordant rates for, 387
 for ductal carcinoma-in-situ, 329
 false-negative rate of, 325-326
 in gastric cancer, 411-412
 for invasive breast cancer, 318-319
 intraoperative, 385-387
 learning curve for, 335
 melanoma and, 333-334
 in Merkel cell cancer, 391
 neoadjuvant chemotherapy and, 330-331
 of head and neck, 387
 previous breast reduction mammoplasty procedures and, 329-330
 prophylactic mastectomy and, 329
 sensitivity rates for, 383
 technical pitfalls of, 378-379
 in thyroid cancer, 390-391
- Sentinel lymph node staging, of solid neoplasms, 404-405
- Sentinel lymph node technique
 in breast cancer, 298-302
 learning of, 333-334
- Serial-section analysis, 312-313
- Shine through, 319-320, 363
- Siewert classification, 444-445
 of gastroesophageal junction adenocarcinoma, 515
- Signal transducers and activators of transcription, 735
- Signet ring cell carcinoma, 467-468
- Similar to Mothers Against Decapentaplegic complex, 478
- Single-voxel spectroscopy, 606-607
- SIOP CNS germ cell tumor 96 trial, 682
- Skip metastasis, in upper gastrointestinal cancer, 409
- Small cell lung cancer, 224
 in esophagus, 471
 extensive-disease, treatment of, 225-227
 limited-disease, treatment of, 224-225
 prophylactic cranial irradiation in, and elderly, 227
- Smoking, esophageal squamous cell carcinoma and, 455, 488
- SN-38, 600
- Social Security Disability Insurance, 287-288
- Socioeconomic status, upper gastrointestinal malignancies and, 457
- Solid tumor(s)
 allogeneic immunotherapy and, 48
 characteristics of, and graft-versus-tumor effect, 48
 nonmyeloablative stem cell transplantation and, 49, 52-53
 radioimmunotherapy of, 71
- Somatic mutation theory, 139-140
- Spindle cell carcinoma, in esophagus, 467
- Squamous cell carcinoma
 of esophagus, 466-467, 487-490
 of oral cavity, 387-390
 variants of, in esophagus, 467
- SRC protein, overexpression of, 479
- St. Anne-Mayo criteria, 620
- ST1571, 630
- Stanford V regimen, 27
- STAT3, 756-757
- Stem cell transplantation
 allogeneic blood, 43
 with alloreactive donor lymphocytes, 6
 blood v marrow for, 43
 mega-dose, 62
 in multiple myeloma, 38-39
- Stereotactic radiosurgery
 in anaplastic astrocytoma, 626
 brain metastasis and, 709-710
 definition of, 709
- Stereotactic resection, computer-assisted, 660
- Stimulated echo acquisition mode, 606-607, 608
- Stimulation mapping, 661-662
- Stomach
 lymph node groups of, 543
 resection of, 546-547
- Stomach cancer
 cross-national mortality due to, 131
 incidence of, by age, 207
 US profile of, 134
- Stress-activated protein kinase, 102-103
- SU5416, 630, 641
- Subareolar plexus technique, 327
- Subcortical pathway, identification of, 662-663
- Subdermal technique, 327
- Suberoylanilide hydroxamic acid, 108
- Submicroscopic disease, 370
- Sucrase-isomaltase, 476
- Suicide, in elderly cancer patients, 276-277
- Sulfur colloid, 319, 326-328
 technetium, 378
- Sunbelt Melanoma trial, 370-371
- Supplemental Security Income, 288
- Surgery
 in localized esophageal cancer, 554-555
 in recurrent glioblastoma multiforme, 639-640
- Surrogate decision-maker, 284-285
- Survival, maximum, v life expectancy, 137-138
- Survivin, 99
- Sweden, elderly population segment in, 129-130
- T classification, 360, 416
- T-cell
 type I, 60-61
 type II, 60-61
- T-cell immunity
 adoptive transfer of, 40-41
 graft rejection and, 56-57
- T-cell population, targeting tumor-associated antigens, 53
- T-cell receptor interaction, 63
- Tacrolimus, methotrexate regimen, 24
- Talampanel, 630
- Tamoxifen, 237-238, 240
- Tarceva, 630, 737, 740
- Targeted antibody therapy, 68-69
- Taxane, 780-781
- Taxol, 819
- Technetium sulfur colloid, 378, 384
- Technologist, cumulative radiation dose to, 302

- Tegafur, uracil, mitomycin regimen, 579
Telomerase, 479
Telomere, 96
 alternate lengthening of, 96-97
Temozolomide, 630, 645
 for brain metastasis, 698
 in elderly, 167-168
Teratoma, radiological findings in, 678
Testicular tumor, in elderly, 260-261
Thalidomide, 630, 641
 in elderly, 168
Therapeutic lymph node dissection, 366
Thermoluminescent dosimeter, 298-299
 for surgical team members, 300-301
Thoracoscopy, in esophageal cancer, 518
Three-item recall, 151
Thymic irradiation, 15
Thyroid cancer, sentinel lymph node biopsy and, 390-391
Tipifarnib, 630
Tirapazamine, 806-807
Tissue sampling, 357-358
TNM classification
 of esophageal carcinoma, 514
 of gastric carcinoma, 519
Tobacco
 environmental, 729
 head and neck cancer and, 727-728
Tobacco smoking
 esophageal squamous cell carcinoma and, 455, 488
 upper gastrointestinal malignancies and, 457
Tonsillar carcinoma, incidence of, 744-745
Topotecan, in elderly, 163-164
Total lymphoid irradiation, 8
Total-body irradiation
 cyclophosphamide regimen, 8
 low-dose, 34
Toxin conjugate, synthesis of, 739
TP53, 500, 503
 mutations in, 447
TP53 gene, 97-98
TP63, 501
Tracer, 377-378
TRAIL, apoptosis and, 105-106
Transforming growth factor, 760-761
Transforming growth factor- α , 478
Transforming growth factor- β 1, 478
Treatment preferences, of elderly, 278
Trichostatin-A, 108
Tubular adenocarcinoma, 467-468
Tumor marker, esophageal squamous cell carcinoma and, 489
Tumor necrosis factor, 60, 760-761
Tumor ulceration, 416-417
Tumor-associated antigen, T-cell population targeting, 53
Tumor-suppressor gene, 596
Two-CDA, dosing of, in renal dysfunction, 163
Tylosis esophageal cancer gene locus, 480-482
Tylosis palmaris, esophageal squamous cell carcinoma and, 490
Tyrosinase reverse-transcriptase polymerase chain reaction, 360-361

UCN-01, 758
Ulceration, of tumor, 416-417

United Kingdom, elderly population segment in, 129-130
United States
 aging profile in, 132
 cancer profile in, 132-133
 elderly population segment in, 129-130
Uracil, tegafur, mitomycin regimen, 579
Urinary bladder cancer, US profile of, 134
Urinary incontinence, in elderly, 150

Vaccine
 donor tumor-antigen, 39
 idiotype, 38, 40-41
Vascular endothelial growth factor, 583, 599, 601, 760-761
Vegetables, upper gastrointestinal malignancies and, 457
Velcade, 583, 630
Veno-occlusive disease, 12
Verrucous carcinoma, in esophagus, 467
Veto mechanism, 63
Vienna classification, 502-503
 revised version of, 502
Villin, 476-477
Vinblastine, carboplatin regimen, in esophageal cancer, 577
Vinblastine, mechlorethamine, doxorubicin, vincristine, bleomycin, etoposide, prednisone, granulocyte colony-stimulating factor regimen, 27
Vincristine, 799
 for malignant glioma, 627
 for oligodendroglioma, 649
Vincristine, etoposide, prednisone, cyclophosphamide, doxorubicin regimen, 42-43
Vincristine, mechlorethamine, doxorubicin, vinblastine, bleomycin, etoposide, prednisone, granulocyte colony-stimulating factor regimen, 27
Vincristine, mechlorethamine, procarbazine, prednisone regimen, 27
Vinorelbine
 in elderly, 167
 in recurrent head and neck cancer, 811
Vinorelbine, cisplatin regimen, 576
Vital staining, esophageal squamous cell carcinoma and, 489
Vitamin A deficiency, esophageal squamous cell carcinoma and, 488
Vulvar cancer, 398-400

WAF-1, 479
Weight loss, in elderly, 150
Welch Allyn Audioscope, 150
Werner's syndrome, 139
WHO classification, of gastric adenocarcinoma, 467-468
WHO schema, 620
Whole brain radiation therapy, 694
 avoidance of, 697
Wiedermann-Tautenstrauch syndrome, 139
Window of immunosuppression, 10
World Health Organization classification
 of lymphoid neoplasms, 200
 of myeloid neoplasms, 186

XAF1, 99

Yttrium 90, 70

ZD1839, 737, 739-740, 601, 630, 641